Genetics in Anti-Platelet Treatment

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Thrombosis Research

Background:

• Anti-platelet drugs are crucial for managing coronary artery disease, ischemic stroke, and peripheral arterial disease.
• A subset of patients exhibits inadequate response to anti-platelet therapy, leading to recurrent atherothrombotic events.
• Variability in patient response to drugs like clopidogrel and aspirin is a significant clinical challenge.

Purpose of the Study:

• To review the genetic factors influencing individual responsiveness to anti-platelet therapy.
• To elucidate the genetic mechanisms underlying low or non-response to anti-platelet medications.
• To highlight the importance of pharmacogenetics in optimizing anti-platelet treatment strategies.

Main Methods:

• Literature review focusing on genetic polymorphisms and their impact on anti-platelet drug efficacy.
• Analysis of studies investigating genetic variations in drug metabolism and target pathways.
• Synthesis of current knowledge on genetic determinants of anti-platelet response.

Main Results:

• Genetic factors significantly contribute to the wide variability in patient response to anti-platelet agents.
• Specific gene variants are associated with reduced efficacy of clopidogrel and aspirin.
• Environmental factors also play a role, interacting with genetic predispositions.

Conclusions:

• Genetic variability is a primary driver of differential responses to anti-platelet drugs.
• Identifying genetic markers can potentially personalize anti-platelet therapy.
• Further research into pharmacogenetics is essential for improving outcomes in patients at risk of atherothrombotic events.